Dawn Svoronos - Jun 14, 2022 Form 4 Insider Report for Global Blood Therapeutics, Inc. (GBT)

Role
Director
Signature
/s/ Miguel Carrillo, Attorney-in-Fact
Stock symbol
GBT
Transactions as of
Jun 14, 2022
Transactions value $
$0
Form type
4
Date filed
6/16/2022, 06:00 PM
Previous filing
Jun 14, 2022
Next filing
Jun 22, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction GBT Common Stock Options Exercise +3.6K +97.72% 7.28K Jun 14, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction GBT Restricted Stock Units Options Exercise $0 -3.6K -100% $0.00* 0 Jun 14, 2022 Common Stock 3.6K Direct F1, F2
transaction GBT Stock Option (Right to Buy) Award $0 +5.6K $0.00 5.6K Jun 14, 2022 Common Stock 5.6K $22.30 Direct F3
transaction GBT Restricted Stock Units Award $0 +3.6K $0.00 3.6K Jun 14, 2022 Common Stock 3.6K Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
F2 The RSUs vested in a single installment on June 14, 2022.
F3 The shares subject to this option shall vest and become exercisable in equal monthly installments over a period of 12 months following June 14, 2022 for 11 months and the remaining 1/12th on the earlier of (i) June 14, 2023 or (ii) the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Issuer's Board of Directors. This option is subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended).
F4 The shares of Common Stock underlying the RSUs vest in a single installment on the earlier of (i) June 14, 2023 or (ii) the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Issuer's Board of Directors. The shares of Common Stock underlying the RSUs are subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended).